News

The positive opinion comes with the recommendation that ciclosporin 0.1% be granted marketing authorisation in the European Union

Lens feathering resulting from intraocular gas can interfere with the visualization needed to perform posterior segment surgery

The trial will evaluate VRDN-001, an intravenously delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

The retrospective study was conducted at King Khaled Eye Specialist Hospital (KKESH), in Riyadh, Saudi Arabia, to review the impact of the COVID-19 pandemic on the training program by comparing the years 2018 and 2019 before the pandemic to 2020 and 2021 after the pandemic.

Sherman practiced in New York for more than 50 years and was the founder of Manhattan Ophthalmology Associates.

Sruthi Arepalli, MD, spoke about her presentation, "Assessing retinal vascular changes in Alzheimer's disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of DED.

Yasha Modi, MD, spoke about the DAVIO phase 2 trial and the upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.

CVD may interfere with an eye care provider’s ability to differentiate between choroidal melanoma and choroidal nevus

Nikoloz Labauri, MD, FVRS, founder of DAVINCI Eye Clinic in Tbilisi, Georgia, discusses his presentation, "Suspensory Macular Buckling for Myopic Traction Maculopathy" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden

A team of researchers in China examined the difference and relationship between optical coherence tomography and optical quality analysis system parameters induced by compound electrolyte intraocular irrigating solution or Ringer lactate solution during uncomplicated cataract surgery.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of geographic atrophy in dry age-related macular degeneration" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Nathan Steinle, MD, spoke about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.

Researchers note work may lead to targets for conventional outflow pathway therapies.

At this year's ASRS meeting, Patrick C. Staropoli, MD, discussed his presentation about autosomal dominant pericentral retinitis pigmentosa

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

Alan Franklin, MD, PhD, FASRS, spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

Richard B. Rosen, MD, recipient of the ASRS Founders Award for 2024, discusses his presentation at the meeting

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

Ashkan Abbey, MD, spoke about his presentation on the CALM registry study, the 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.

According to the company, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

Therapeutics can prevent vision loss and neurodegeneration in patients.